HomeCompareEBIX vs JNJ

EBIX vs JNJ: Dividend Comparison 2026

EBIX yields 25.86% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EBIX wins by $70.5K in total portfolio value
10 years
EBIX
EBIX
● Live price
25.86%
Share price
$1.16
Annual div
$0.30
5Y div CAGR
-0.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$100.8K
Annual income
$11,306.07
Full EBIX calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — EBIX vs JNJ

📍 EBIX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodEBIXJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, EBIX + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
EBIX pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

EBIX
Annual income on $10K today (after 15% tax)
$2,198.28/yr
After 10yr DRIP, annual income (after tax)
$9,610.16/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, EBIX beats the other by $5,624.17/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of EBIX + JNJ for your $10,000?

EBIX: 50%JNJ: 50%
100% JNJ50/50100% EBIX
Portfolio after 10yr
$65.5K
Annual income
$7,997.74/yr
Blended yield
12.20%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

EBIX
Analyst Ratings
1
Buy
2
Hold
Consensus: Hold
Price Target
$100.00
+8520.7% upside vs current
Range: $100.00 — $100.00
Altman Z
1.0
Piotroski
6/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

EBIX buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricEBIXJNJ
Forward yield25.86%2.13%
Annual dividend / share$0.30$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-0.4%28%
Portfolio after 10y$100.8K$30.3K
Annual income after 10y$11,306.07$4,689.40
Total dividends collected$64.1K$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusHoldBuy
Analyst price target$100.00$228.73

Year-by-year: EBIX vs JNJ ($10,000, DRIP)

YearEBIX PortfolioEBIX Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$13,276$2,575.86$10,592$272.30+$2.7KEBIX
2$17,388$3,183.18$11,289$357.73+$6.1KEBIX
3$22,486$3,880.90$12,123$472.89+$10.4KEBIX
4$28,732$4,671.64$13,141$629.86+$15.6KEBIX
5$36,300$5,556.39$14,408$846.81+$21.9KEBIX
6$45,375$6,534.38$16,021$1,151.60+$29.4KEBIX
7$56,155$7,603.15$18,122$1,588.22+$38.0KEBIX
8$68,844$8,758.63$20,930$2,228.20+$47.9KEBIX
9$83,658$9,995.24$24,792$3,191.91+$58.9KEBIX
10$100,820$11,306.07$30,274$4,689.40+$70.5KEBIX

EBIX vs JNJ: Complete Analysis 2026

EBIXStock

Ebix, Inc., together with its subsidiaries, provides on-demand infrastructure software exchanges and e-commerce services to the insurance, financial, travel, and healthcare industries in the United States and internationally. It develops and deploys insurance and reinsurance exchanges; provides software-as-a-service (SaaS) enterprise solutions in the areas of customer relationship management, and front-end and back-end systems; and offers outsourced administrative and risk compliance solutions. The company operates P&C exchanges primarily in Australia, New Zealand, the United Kingdom, and the United States, which facilitates the exchange of insurance data between brokers and insurance carriers with a focus on the areas of personal and commercial lines. Its exchange related products and services include travel exchanges and money transfer services; foreign exchange and outward remittance services; payment services; gift cards for consumers that can be redeemed at various merchants; and technology services for various providers in the areas of lending, wealth and asset management, and travel. The company's insurance exchanges related products and services include SaaS platform and related services; licensing of software; and professional services comprising setting up, customization, training, or consulting. Its risk compliance services cover certificates of insurance creation and tracking; consulting services comprising project management and development; and business process outsourcing services, including domain intensive project management, system consulting services, and claims adjudication/settlement services. The company was formerly known as Delphi Systems, Inc. and changed its name to Ebix, Inc. in December 2003. Ebix, Inc. was founded in 1976 and is headquartered in Johns Creek, Georgia.

Full EBIX Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this EBIX vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

EBIX vs SCHDEBIX vs JEPIEBIX vs OEBIX vs KOEBIX vs MAINEBIX vs ABBVEBIX vs MRKEBIX vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.